Briken Peer, Berner Wolfgang
Institute for Sex Research and Forensic Psychiatry, Interdisciplinary Competence Centre for Sexual Health, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Isr J Psychiatry Relat Sci. 2012;49(4):306-13.
The treatment of paraphilias, especially of pedophilia, centers upon cognitive-behavioral psychotherapy and pharmacologic interventions. Two open, uncontrolled clinical studies using the synthetic LHRH-agonist triptorelin suggested that, combined with psychotherapy, antiandrogen treatment reduced deviant sexual fantasies, urges, and behaviors in paraphilic patients. There is a need for further research using controlled, randomized trials to examine the effectiveness of sexual offender treatment including psychotherapeutic and pharmacologic interventions.
The aim of this pilot study is to evaluate the efficacy and tolerability of cognitive-behavioral psychotherapy together with intramuscular (IM) 3-monthly injections of triptorelin in adult men with severe pedophilia.
In this multicenter, forensic psychiatric hospital-based, double-blind, controlled, parallel group phase IV trial conducted in Germany, convicted male sexual offenders aged ≥ 18 years with pedophilia, as defined by DSM-IV-TR criteria, will be randomized to receive study-specific psychotherapy together either with triptorelin or placebo for 12 months (total of 4 injections). This is a pilot study, therefore exploratory data analyses will be carried out of three different target parameters: 1. Changes in psychosexual characteristics using the Multiphasic Sex Inventory (scale: sexual abuse of children) 2. Changes in the risk of violent sexual behavior using the Sexual Violence Risk-20 total score 3. Changes in serum testosterone concentration Treatment effects will be assessed by comparing baseline values with those at the final examination (month 12).
The absence of real-life stimulants to test for actual recidivism limits possible findings. The study will be conducted in agreement with the European GCP-guideline, all relevant legal requirements, and the legal framework for voluntary treatment of convicted sexual offenders in Germany.
性偏好障碍的治疗,尤其是恋童癖的治疗,主要围绕认知行为心理治疗和药物干预展开。两项使用合成促性腺激素释放激素(LHRH)激动剂曲普瑞林的开放性、非对照临床研究表明,与心理治疗相结合,抗雄激素治疗可减少性偏好障碍患者的异常性幻想、冲动及行为。有必要开展进一步的对照随机试验研究,以检验包括心理治疗和药物干预在内的性犯罪者治疗方法的有效性。
本试点研究旨在评估认知行为心理治疗联合每三个月肌肉注射一次曲普瑞林,对成年重度恋童癖男性的疗效和耐受性。
在德国进行的这项多中心、基于法医精神病院的双盲、对照、平行组IV期试验中,年龄≥18岁、符合《精神疾病诊断与统计手册》第四版修订版(DSM-IV-TR)标准定义的恋童癖男性性犯罪者将被随机分组,接受特定的心理治疗,同时分别注射曲普瑞林或安慰剂,为期12个月(共4次注射)。这是一项试点研究,因此将对三个不同的目标参数进行探索性数据分析:1. 使用多相性量表(量表:对儿童的性虐待)评估性心理特征的变化;2. 使用性暴力风险-20总分评估性暴力行为风险的变化;3. 血清睾酮浓度的变化。通过比较基线值与最终检查(第12个月)时的值来评估治疗效果。
缺乏用于测试实际再犯情况的现实生活刺激因素限制了可能的研究结果。本研究将按照欧洲药品临床试验质量管理规范指南、所有相关法律要求以及德国对被定罪性犯罪者自愿治疗的法律框架进行。